Raymond James’s $19 target on VIR

VIR Vir Biotechnology Inc

$10.5 → $19 (+81%) by Sep 2027

Strong Buy · reiterates · said Sep 28, 2026 · 12-month default horizon

Open: judged on the close on Sep 28, 2027

The article this target came from

Raymond James reiterates Vir Biotechnology stock rating on hepatitis delta data

Investing.com · Sep 28, 2026

Raymond James reiterated a Strong Buy rating and $19.00 price target on Vir Biotechnology stock

Raymond James’s track record → Vir Biotechnology Inc →

A fact about what Raymond James published, as reported by Investing.com, not a recommendation from Dalsna Finance; Raymond James is not affiliated with this site.

Full methodology: how targets are collected, scored, ranked and corrected, what each field means, and how to cite the data.